CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 9 enrolled
Drug / intervention
Hypericindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05380635
NCT05380635Phase 2Completed
CompareCT.gov

Phase 2a Study of Systemic PK and Serial ECG Determinations Following 8 Weeks of HyBryte Treatment

Soligenix·interventional·Posted May 19, 2022·Updated Jun 7, 2023

In Brief

A Phase 2 clinical trial evaluating Hypericin for Cutaneous T-Cell Lymphoma/Mycosis Fungoides. Completed, enrolled 9 participants across 1 site.

Detailed Summary

To assess the blood levels of hypericin and any electrocardiogram (ECG) changes during 8 weeks of HyBryte (topical hypericin ointment) photodynamic therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCutaneous T-Cell Lymphoma/Mycosis Fungoides
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedMay 19, 2022
Enrollment StartMay 9, 2022
Primary CompletionAug 16, 2022
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 4.1 years ago

Interventions

Hypericindrug

HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment.